These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

436 related items for PubMed ID: 32087233

  • 1. Whole body hypothermia extends tissue plasminogen activator treatment window in the rat model of embolic stroke.
    Hassanipour M, Zarisfi M, Ehsani V, Allahtavakoli M.
    Life Sci; 2020 Sep 01; 256():117450. PubMed ID: 32087233
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Ascorbic Acid Reduces the Adverse Effects of Delayed Administration of Tissue Plasminogen Activator in a Rat Stroke Model.
    Allahtavakoli M, Amin F, Esmaeeli-Nadimi A, Shamsizadeh A, Kazemi-Arababadi M, Kennedy D.
    Basic Clin Pharmacol Toxicol; 2015 Nov 01; 117(5):335-9. PubMed ID: 25899606
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke.
    Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M.
    Circulation; 2002 Aug 06; 106(6):740-5. PubMed ID: 12163437
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Extension of the thrombolytic time window with minocycline in experimental stroke.
    Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH.
    Stroke; 2008 Dec 06; 39(12):3372-7. PubMed ID: 18927459
    [Abstract] [Full Text] [Related]

  • 11. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model.
    Zhang L, Zhang ZG, Zhang C, Zhang RL, Chopp M.
    Stroke; 2004 Dec 06; 35(12):2890-5. PubMed ID: 15514182
    [Abstract] [Full Text] [Related]

  • 12. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator.
    Roncal C, Martinez de Lizarrondo S, Salicio A, Chevilley A, Rodriguez JA, Rosell A, Couraud PO, Weksler B, Montaner J, Vivien D, Páramo JA, Orbe J.
    Cardiovasc Res; 2017 Aug 01; 113(10):1219-1229. PubMed ID: 28379489
    [Abstract] [Full Text] [Related]

  • 13. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.
    Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, Zlokovic BV.
    Stroke; 2012 Sep 01; 43(9):2444-9. PubMed ID: 22811462
    [Abstract] [Full Text] [Related]

  • 14. Phosphorylated recombinant HSP27 protects the brain and attenuates blood-brain barrier disruption following stroke in mice receiving intravenous tissue-plasminogen activator.
    Shimada Y, Shimura H, Tanaka R, Yamashiro K, Koike M, Uchiyama Y, Urabe T, Hattori N.
    PLoS One; 2018 Sep 01; 13(5):e0198039. PubMed ID: 29795667
    [Abstract] [Full Text] [Related]

  • 15. Comparative Analysis of Different Methods of Ischemia/Reperfusion in Hyperglycemic Stroke Outcomes: Interaction with tPA.
    Hafez S, Hoda MN, Guo X, Johnson MH, Fagan SC, Ergul A.
    Transl Stroke Res; 2015 Jun 01; 6(3):171-80. PubMed ID: 25683354
    [Abstract] [Full Text] [Related]

  • 16. Bryostatin extends tPA time window to 6 h following middle cerebral artery occlusion in aged female rats.
    Tan Z, Lucke-Wold BP, Logsdon AF, Turner RC, Tan C, Li X, Hongpaison J, Alkon DL, Simpkins JW, Rosen CL, Huber JD.
    Eur J Pharmacol; 2015 Oct 05; 764():404-412. PubMed ID: 26189021
    [Abstract] [Full Text] [Related]

  • 17. Combination therapy with liposomal neuroprotectants and tissue plasminogen activator for treatment of ischemic stroke.
    Fukuta T, Asai T, Yanagida Y, Namba M, Koide H, Shimizu K, Oku N.
    FASEB J; 2017 May 05; 31(5):1879-1890. PubMed ID: 28082354
    [Abstract] [Full Text] [Related]

  • 18. Pinocembrin Protects Blood-Brain Barrier Function and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in a Rat Thromboembolic Stroke Model.
    Ma Y, Li L, Kong L, Zhu Z, Zhang W, Song J, Chang J, Du G.
    Biomed Res Int; 2018 May 05; 2018():8943210. PubMed ID: 29850586
    [Abstract] [Full Text] [Related]

  • 19. Effects of tissue plasminogen activator timing on blood-brain barrier permeability and hemorrhagic transformation in rats with transient ischemic stroke.
    Zhang Y, Wang Y, Zuo Z, Wang Z, Roy J, Hou Q, Tong E, Hoffmann A, Sperberg E, Bredno J, Berr SS, Xie M, Lee K, Wintermark M.
    J Neurol Sci; 2014 Dec 15; 347(1-2):148-54. PubMed ID: 25292413
    [Abstract] [Full Text] [Related]

  • 20. Dodecafluoropentane Emulsion Extends Window for tPA Therapy in a Rabbit Stroke Model.
    Culp WC, Brown AT, Lowery JD, Arthur MC, Roberson PK, Skinner RD.
    Mol Neurobiol; 2015 Oct 15; 52(2):979-84. PubMed ID: 26055229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.